Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Fear Response

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44379   clinical trials with a EudraCT protocol, of which   7391   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    22 result(s) found for: Fear Response. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2016-005013-47 Sponsor Protocol Number: FAAH2 Start Date*: 2017-02-28
    Sponsor Name:Linköping University
    Full Title: Effects of the FAAH inhibitor PF-04457845 on fear extinction in healthy volunteers
    Medical condition: Healthy volunteers (extinction of fear)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10037175 - Psychiatric disorders 10016275 Fear PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023849-30 Sponsor Protocol Number: CSCAbrein&cognitie1-04 Start Date*: Information not available in EudraCT
    Sponsor Name:University of Amsterdam
    Full Title: The effects of MR and GR blockade on the reconsolidation and extinction of fear memories
    Medical condition: Fear conditioning acquisition, reconsolidation and extinction in healthy male subjects.
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002392-10 Sponsor Protocol Number: S59302 Start Date*: 2017-02-02
    Sponsor Name:UZ Leuven
    Full Title: Reconsolidation interference versus retrieval interference as the basis for experimental amnesia in humans – The effect of drug state at memory retrieval
    Medical condition: Experimental study with healthy participants recruited from the general population; no vulnerable individuals or clinical groups will be involved. Our objective is to test wether the internal drug ...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-003739-62 Sponsor Protocol Number: 2021-74835 Start Date*: 2021-06-23
    Sponsor Name:University Medical Center Utrecht
    Full Title: BOOSTCAMP: Boosting the endocannabinoid system before the treatment of anxiety symptoms
    Medical condition: PTSD and anxiety disorders
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-000133-13 Sponsor Protocol Number: 2020-01131 Start Date*: 2022-05-05
    Sponsor Name:Universitätsmedizin Göttingen
    Full Title: Glucocorticoid enhancement of food exposure therapy in Binge Eating Disorder
    Medical condition: Binge-Eating-Disorder
    Disease: Version SOC Term Classification Code Term Level
    24.0 10037175 - Psychiatric disorders 10004716 Binge eating PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000712-30 Sponsor Protocol Number: ABR-71432 Start Date*: 2021-06-07
    Sponsor Name:Radboudumc
    Full Title: Targeted glucocorticoid administration to improve safety learning in PTSD patients with HPA axis dysregulation
    Medical condition: Posttraumatic Stress Disorder (PTSD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10036876 Prolonged posttraumatic stress disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-002407-18 Sponsor Protocol Number: Start Date*: 2012-08-14
    Sponsor Name:University of Dundee and NHS Tayside [...]
    1. University of Dundee and NHS Tayside
    2. NHS Tayside
    Full Title: DPP4 inhibitors in Type 1 Diabetes
    Medical condition: Type 1 Diabetes
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-003191-39 Sponsor Protocol Number: Start Date*: 2013-01-21
    Sponsor Name:University of Oxford
    Full Title: The effect of a single-dose of d-cycloserine on the basic effects of cognitive-behaviour therapy for panic disorder - a randomized placebo-controlled trial
    Medical condition: DSM-IV Panic disorder
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004873 10068300 Panic attacks and disorders HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003542-68 Sponsor Protocol Number: Start Date*: 2016-01-27
    Sponsor Name:University of Oxford
    Full Title: The effect of single-dose losartan on the basic effects of cognitive-behaviour therapy for panic disorder - a randomized double blind placebo-controlled trial
    Medical condition: DSM panic disorder
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004873 10068300 Panic attacks and disorders HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2006-003659-19 Sponsor Protocol Number: R317573DEP2002 Start Date*: 2006-09-14
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Double Blind, Placebo- and Active-Controlled, Randomized, Sequential Group, Multiple Dose Study to Examine the Effect of the CRF1-Receptor Antagonist R317573 on 7.5% CO2-Inhalation Induced Anxiet...
    Medical condition: Anxiety disorders and depression
    Disease: Version SOC Term Classification Code Term Level
    8.1 10057666 Anxiety disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-002968-27 Sponsor Protocol Number: INTERMEDIATE-01 Start Date*: 2020-02-18
    Sponsor Name:Centre François Baclesse
    Full Title: Multicentric phase III trial comparing two strategies in intermediate-risk differentiated thyroid cancer patients: Systematic radioiodine administration (3.7 GBq I131 after rhTSH) versus decision o...
    Medical condition: Differentiated thyroid cancer - subgroup of patients with intermediate risk of postoperative residual disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066474 Thyroid cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-023044-32 Sponsor Protocol Number: DCS-fMRIPanik Start Date*: 2011-08-10
    Sponsor Name:Charité Universitaetsmedizin Berlin
    Full Title: Mechanisms of action in exposure therapy: Decoding the neural basis of fear extinction and its pharmacological modulation in patients with panic disorder
    Medical condition: panic disorder and agoraphobia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-000454-22 Sponsor Protocol Number: NL43068.058.13 Start Date*: 2013-08-21
    Sponsor Name:
    Full Title: (Grand)parenting, oxytocin, and the oxytocin receptor gene: an fMRI and observational study
    Medical condition: There are no medical conditions or diseases under investigation
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022891 - Investigations 10033329 Oxytocin PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-004818-34 Sponsor Protocol Number: CTRIAL-IE-19-32 Start Date*: 2021-04-23
    Sponsor Name:Cancer Trials Ireland
    Full Title: DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801). A randomised phase 3 double-blind, placebo-controlled trial of adding darolutamid...
    Medical condition: Clinically localised prostate cancer defined as very high risk, or with very high risk features.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-001627-32 Sponsor Protocol Number: CVAY736Q12301 Start Date*: 2023-03-15
    Sponsor Name:Novartis Pharma AG
    Full Title: A phase 3 randomized, double-blind study of ianalumab (VAY736) versus placebo in addition to eltrombopag in patients with primary immune thrombocytopenia (ITP) who had an insufficient response or r...
    Medical condition: immune thrombocytopenia (ITP)
    Disease: Version SOC Term Classification Code Term Level
    23.0 10005329 - Blood and lymphatic system disorders 10083842 Immune thrombocytopenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) CZ (Trial now transitioned) HU (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned) NO (Trial now transitioned) ES (Ongoing) AT (Trial now transitioned) BE (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-001248-67 Sponsor Protocol Number: LIN4113 Start Date*: 2014-01-14
    Sponsor Name:almirall
    Full Title: CLINICAL TRIAL PHASE IIIb to evaluate predictors of response to linaclotide in patients with irritable bowel syndrome and explore the impact on intestinal symptoms
    Medical condition: Irritable bowel syndrome
    Disease: Version SOC Term Classification Code Term Level
    16.1 10017947 - Gastrointestinal disorders 10023003 Irritable bowel syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-002790-94 Sponsor Protocol Number: 200828 Start Date*: 2020-09-16
    Sponsor Name:SLSO
    Full Title: The Effect of Psilocybin on MDD Symptom Severity and Synaptic Density – A Single Dose Randomized, Double Blind, Placebo-Controlled Phase 2 Positron Emission Tomography Study
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10025462 Major depressive disorder, recurrent episode, unspecified degree LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002063-60 Sponsor Protocol Number: PRN1008-018(EFC17093) Start Date*: 2020-11-12
    Sponsor Name:Principia Biopharma, Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel-Group Study with an Open-Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib (PRN1008) in Adults...
    Medical condition: Immune Thrombocytopenia (ITP)
    Disease: Version SOC Term Classification Code Term Level
    23.0 10005329 - Blood and lymphatic system disorders 10074667 Immune thrombocytopenic purpura LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) GB (GB - no longer in EU/EEA) PL (Trial now transitioned) AT (Completed) NO (Trial now transitioned) FR (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000615-23 Sponsor Protocol Number: UC-IMM-2101 Start Date*: 2021-06-17
    Sponsor Name:UNICANCER
    Full Title: Randomized phase III trial of standard immunotherapy (IO) by checkpoint inhibitors, versus reduced dose intensity of IO in patients with metastatic cancer in response after 6 months of standard IO
    Medical condition: Oncologic metastatic tumour (lung cancer (K), renal cell K (except IMDC favorable-risk treated TKI / immunotherapy [IO] combination), head and neck K, bladder K, triple negative breast K, Merkel K ...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025044 Lung cancer LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038407 Renal cell cancer LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10053571 Melanoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10064025 Merkel cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-001302-30 Sponsor Protocol Number: ACOVACT Start Date*: 2020-04-15
    Sponsor Name:Medical University of Vienna
    Full Title: A multicenter, randomized, active controlled, open label, platform trial on the efficacy and safety of experimental therapeutics for patients with COVID-19 (caused by infection with severe acute re...
    Medical condition: Infection with SARS-COV-2 (=COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021881 - Infections and infestations 10035737 Pneumonia viral PT
    21.1 100000004855 10003083 ARDS LLT
    20.0 10021881 - Infections and infestations 10038700 Respiratory infection LLT
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Feb 08 19:23:02 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA